First-in-human, Open-label, Phase 1 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Select Advanced Malignant Solid Tumors
Latest Information Update: 06 Mar 2026
At a glance
- Drugs GEN 1079 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Genmab
Most Recent Events
- 19 Feb 2026 Status changed from not yet recruiting to recruiting.
- 11 Feb 2026 New trial record